E levated cholesterol levels have been long known to be a strong risk factor for cardiovascular disease, myocardial infarction, and stroke (1) (2) (3) . Screening for dyslipidemia can identify asymptomatic individuals at risk for atherosclerotic cardiovascular disease (ASCVD), allowing them to pursue lifestyle interventions or medical therapy. The 2013 cholesterol management guidelines from the American College of Cardiology and American Heart Association (ACC/AHA) recommend an initial lipid panel for all adults older than 20 years followed by repeated testing every 4 to 6 years to identify those at high risk for ASCVD (4) . For primary prevention, the high-risk population has been defined as adults with a 10-year risk for ASCVD greater than 7.5% or a lifetime risk greater than 30%, as well as those with very high low-density lipoprotein cholesterol (LDL-C) levels or primary genetic hyperlipidemias, for whom models may not accurately reflect risk (5) . In contrast, the 2008 guideline from the U.S. Preventive Services Task Force (USPSTF) recommended initial screening at age 35 years for men and 45 years for women unless 1 or more traditional risk factors for atherosclerosis are present (6) . One reason for this discrepancy is the lack of clinical trial evidence to support cholesterol screening for primary prevention in the young adult population (7) .
Because total and high-density lipoprotein cholesterol (HDL-C) levels must be determined to calculate ASCVD risk, the decision to institute primary prevention requires a screening cholesterol level. However, on the basis of the underlying distribution of cholesterol in the population, it may be possible to identify patients who, because of their lack of other risk factors, are very unlikely to have an ASCVD risk high enough to warrant treatment and therefore are unlikely to benefit from cholesterol screening. To help decide whether to use the approach of the ACC/AHA or that of the USPSTF, we aimed to describe the prevalence of elevated ASCVD risk in young adults by extrapolating the pooled cohort risk prediction equation to a nationally representative sample of adults aged 30 to 49 years. We identified the prevalence of elevated 10-year AS-CVD risk in several subgroups based on age, sex, smoking status, and the presence of hypertension. We also described the prevalence of very high LDL-C 
METHODS

Study Design and Participants
This study involved a cross-sectional analysis of adults aged 30 to 49 years who participated in the examination component of NHANES (National Health and Nutrition Examination Survey) (8) . The survey, conducted by the Centers for Disease Control and Prevention and the National Center for Health Statistics (NCHS), uses a complex, multistage, clustered probability method to sample noninstitutionalized U.S. civilians to provide nationally representative estimates. NHANES data from 1999 to 2000 through 2011 to 2012 were analyzed; the sample from 2013 to 2014 was excluded because prescription drug data are not yet available for those years. Participants with missing data and those with self-reported stroke, coronary artery disease, other cardiovascular disease (congestive heart failure, myocardial infarction, or angina), or diabetes were excluded. In our primary analysis, we also excluded persons who were already receiving a statin or any other lipid-lowering drug at the time of the visit during which lipid profiles were drawn, because the results would not represent their true lipid levels; however, these participants were included in a sensitivity analysis. All participants provided written informed consent. The study protocol was approved by the NCHS Institutional Review Board (8) .
Covariates
We used the following self-reported information: age, sex, race, smoking status, and treatment with antihypertensive medications. Systolic blood pressure, total cholesterol, and HDL-C measurements were available and included for all examined participants, but only those in the morning session had fasting LDL-C and triglyceride measurements. Although a standardized laboratory protocol was used for all lipid analyses, some changes occurred in the laboratories, methods, and instruments used to measure these values during the study period (9) . The Friedewald equation was used to calculate LDL-C levels for participants with a triglyceride level of 4.52 mmol/L (400 mg/dL) or greater. Hypertension was defined as blood pressure of 140/90 mm Hg or greater (on an average of 3 or more readings), as measured at the NHANES examination; selfreport that a physician or health professional diagnosed hypertension on at least 2 different occasions; or current antihypertensive drug treatment. NHANES participants began self-reporting family history of premature ASCVD (that is, heart attack in a first-degree relative before age 50 years) in the surveys of 2005 to 2006.
Definition of Elevated Cardiovascular Risk and Low-Prevalence Groups
The purpose of our study was to identify subgroups for which cholesterol screening would not provide actionable information. Therefore, we defined elevated cardiovascular risk as a 10-year ASCVD risk greater than 5%-the lowest ASCVD risk at which statin therapy might be considered according to the guidelines-by using the 2013 ACC/AHA ASCVD pooled cohort equation (5) . Because the equation may overestimate risk in low-risk patients (10 -12) , our choice represents a conservative threshold that might be more sensitive in younger age groups (13). We then created subgroups of participants based on age, sex, and history of smoking and hypertension and calculated the prevalence of elevated cardiovascular risk within each subgroup. We found no studies to inform a threshold prevalence of risk that would justify screening. We defined lowprevalence subgroups as those in which we could rule out a greater than 1% prevalence of elevated cardiovascular risk (that is, the upper bound of the 95% confidence limit was ≤1%). This estimate seemed reasonably conservative, because the number needed to treat with statins to prevent 1 fatal or nonfatal coronary heart disease event in primary prevention is approximately 56 (14) . At a prevalence lower than 1%, the number needed to screen to prevent 1 cardiovascular event would be at least 100 times greater (that is, >5600).
Definition of Elevated LDL-C Level
To identify participants with LDL-C levels high enough to directly qualify for statin treatment, we estimated the proportion of adults with LDL-C levels of at least 4.92 mmol/L (190 mg/dL), which is the recommended screening threshold for identifying patients with familial hyperlipidemia (15) . To evaluate the utility of targeted screening of young adults for familial hyperlipidemia in those with a self-reported family history of premature ASCVD, we assessed whether the proportion of participants with LDL-C levels of at least 4.92 mmol/L (190 mg/dL) differs according to the presence of a positive family history of premature ASCVD (15) .
Statistical Analysis
We generated nationally representative prevalence estimates after incorporating appropriate 2-or 4-year sample weights (for the main analysis) or morning fasting subsample weights (for the LDL-C analyses), which accounted for the complex, multistage, probability sampling design of the NHANES (16). We used appropriate morning fasting subsample weights for the subgroup of participants with data available on both LDL-C and family history (2005 to 2006 through 2011 to 2012), according to NCHS instructions (16). Standard errors were obtained by using first-order Taylor series linearization (17) . Confidence intervals were constructed by using logit transformation for subgroups with positive numbers of persons at elevated risk or an exact binomial method for subgroups with 0 individuals at elevated risk (9, 18) . These prevalence estimates were intended to represent the civilian, noninstitutionalized U.S. population aged 20 years and older. We compared differences in the proportion of participants with elevated LDL-C levels between those with and those without a family history of premature ASCVD by using the Pearson chi-square test and appropriate sample weights to account for the survey design. In sensi-
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ORIGINAL RESEARCH tivity analyses, we included participants who were receiving lipid-lowering drugs and estimated their lipid profiles (and corresponding 10-year ASCVD risk) in the absence of these medications. Specifically, on the basis of previous studies, we assumed that lipid-lowering drugs reduced total cholesterol by 21.18% and raised HDL-C by 3.57% (19) . All analyses accounted for complex survey design and appropriate subgroup weighting. The NHANES analyses were performed by using the "svy" prefix to the "prop" command (with the "subpop" option for subpopulations, such as persons with LDL-C ≥4.92 mmol/L [190 mg/dL]) and the "over" option for between-group comparisons (such as males vs. females) in Stata/MP 13.1 (StataCorp).
Role of the Funding Source
The study was not funded.
RESULTS
Of 10 862 NHANES participants aged 30 to 49 years, 1003 were excluded for having diabetes (n = 735), for having ASCVD or one of its equivalents (stroke, n = 116; coronary artery disease, n = 72; or other cardiovascular disease, n = 223), or missing data (n = 197), and 251 were excluded because they were already receiving statin therapy at the time of their visit. Our final population consisted of 9608 persons representing 67.9 million U.S. adults. The characteristics of the population are described in Table 1 .
Overall, 9.1% (95% CI, 8.3% to 9.9%) of adults had a 10-year estimated ASCVD risk greater than 5% (that is, an elevated risk). Table 2 shows the percentage of patients with elevated cardiovascular risk in subgroups of young adults divided by age, sex, and risk factors of smoking and hypertension. The percentage of adults with elevated risk varied substantially (from 0% to 75.9%) by age, sex, and smoking and hypertension status. In the absence of smoking or hypertension, adult men younger than 40 years and adult women younger than 50 years constituted the low-prevalence subgroups (indicated in the table by boldface type).
Of nonsmoking, nonhypertensive women younger than 50 years, 0.04% (CI, 0.0% to 0.26%) had an elevated cardiovascular risk. Of nonsmoking, nonhypertensive men younger than 40 years, 0.09% (CI, 0.02% to 0.35%) had an elevated cardiovascular risk. About half the young adult population aged 30 to 49 years (47.12%) was in the low-prevalence subgroups. Of the few adults who had elevated risk in these lowprevalence groups, all had a risk between 5.0% and 7.4% (Table 3) . Nonsmoking adults with hypertension had an intermediate prevalence of elevated risk (ranging from 0% to 29.3% depending on age and sex). At every age, smokers had the highest prevalence of elevated cardiovascular risk. Sensitivity analyses including patients receiving lipid-lowering drugs demonstrated similar results and identified the same low-prevalence subgroups, except that the 95% CI for women aged 45 to 49 years without risk factors crossed 1% (Appendix Table 1 , available at Annals.org). 
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Low-density lipoprotein cholesterol levels of at least 4.92 mmol/L (190 mg/dL) were present in 2.9% (CI, 2.3% to 3.5%) of young adults in NHANES. Of these adults, 1.7% (CI, 1.1% to 2.4%) in the low-prevalence groups had an LDL-C level of at least 4.92 mmol/L (190 mg/dL). The proportion of adults with an LDL-C level of at least 4.92 mmol/L (190 mg/dL) was greater in the presence of smoking and hypertension (Appendix Table 2, available at Annals.org). On the basis of our sample of 2562 young adults aged 30 to 49 years for whom data on both LDL-C level and family history were available, 11.4% (CI, 9.9% to 12.9%) had a family history of premature ASCVD. In both men and women, the proportion with LDL-C levels of 4.92 mmol/L (190 mg/dL) or greater did not differ by family history ( Table 4) .
DISCUSSION
In this cross-sectional analysis of a nationally representative population, we found that the prevalence of elevated cardiovascular risk was low in normotensive, nonsmoking women younger than 50 years (about 22.2 million women) and men younger than 40 years (about 9.8 million men). This group constituted one half of the population aged 30 to 49 years, representing 32 million people. Only 1.7% (CI, 1.1% to 2.4%) of these lowrisk adults had an LDL-C level of at least 4.92 mmol/L (190 mg/dL), and they were no more likely to report a family history of premature heart attack than those with lower LDL-C levels. Given the low prevalence of patients at elevated cardiovascular risk, our findings would support the targeted approach of the USPSTF over the more general screening of the ACC/AHA. However, given the observed risk distribution, screening for adults without risk factors might begin at age 40 years for men and 50 years for women.
The primary purpose of checking serum cholesterol levels in healthy patients is to identify those who would benefit from lipid-lowering therapy. This group includes patients with an elevated risk for cardiac events on the basis of the pooled cohort equation, as well as those whose cholesterol levels are extremely high, indicating probable familial hypercholesterolemia. The latter group is thought to have an accelerated risk for ASCVD (20), and initiation of statin treatment helps reduce their risk early in the course of treatment (21, 22) . The 2013 ACC/AHA guidelines recommend treatment with a statin for patients with a 10-year risk of 7.5% or greater, although statin treatment may be considered even for those with a 5% risk (5) . In contrast, the USPSTF recommends treating only patients with a 10-year risk of 10% and at least 1 cardiac risk factor (23). We examined the probability of patients having a risk greater than 5% to decide a priori whether testing made sense. Because the data regarding risk prediction for the young adult population are sparse (4, 7), we extrapolated the pooled cohort equations to this subgroup. Regarding young patients without risk factors, we found that very few (<0.5%) had a calculated risk greater than 5%. Moreover, this threshold may be overly aggressive, because several studies have found that the pooled cohort equation overestimates risk in low-risk patients (11, 12) , especially women (10). Using a higher threshold (for example, 7.5%) would make screening these groups even less efficient, because there were no patients in these subgroups with a risk greater than 7.5%. Some might argue that patients with risk levels in the 1% to 4% range should be made aware of their risk so that they can undertake therapeutic lifestyle changes. However, no evidence exists that showing patients they are at low risk will prompt positive behavior changes, and it might even have the opposite effect. A patient's choice not to make lifestyle changes would be unfortunate, because a healthy lifestyle, including proper diet and exercise, is beneficial for preventing both cardiovascular and noncardiovascular diseases and should be recommended for everyone regardless of cholesterol level (24) .
Another argument for testing and potentially treating younger patients is related to lifetime cardiac risk (5) . Although 10-year risk may be low, preventing atherosclerosis might prevent disease 20, 30, or even 40 years in the future. However, no trials have been done to inform such a strategy, and treatment in later years is so effective (25) that it is unclear how much additional benefit would result from initiating treatment early (7) . Moreover, statin treatment may increase risk for diabetes (26) , which might outweigh cardiovascular benefits in younger patients. More research is needed before statins can be recommended on the basis of lifetime risk alone.
Lastly, universal screening might be used to identify people with familial hyperlipidemia, who have early disease (20) and might benefit from early treatment with statins. A recent NHANES analysis using clinical criteria estimated the prevalence of familial hypercholesterolemia as 1 in 250, which rises with increasing age and obesity (27) . However, only a very small fraction of patients with LDL-C levels of 4.92 mmol/L (190 mg/dL) or greater have a genetic mutation for familial hyperlipidemia (28) . Identifying a broader population as poten- Heart Association sex-and race-specific pooled cohort equations. Low-prevalence subgroups are defined as those in which we could rule out a prevalence of elevated cardiovascular risk (10-y ASCVD risk >5%) >1% and included male nonsmokers without hypertension aged <40 y and female nonsmokers without hypertension aged <50 y.
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ORIGINAL RESEARCH tially having familial hyperlipidemia might lead to more testing or, potentially, to overtreatment. In the present study, 2.9% of the population had LDL-C values of at least 4.92 mmol/L (190 mg/dL); 90% of this subgroup presumably did not have familial hypercholesterolemia. Moreover, these patients were not more likely to have a family history of premature ASCVD. The distribution of ASCVD risk in adults younger than 50 years has been studied by other researchers. In a study using earlier NHANES data, 95.7% of adults aged 30 to 39 years and 89.7% of those aged 40 to 49 years had a 10-year risk lower than 10%, on the basis of the Framingham risk equation, in the absence of ASCVD or risk equivalents (29) . Because this study preceded the 2013 guidelines, the authors did not address the 5% threshold. In a more recent analysis of risk distribution using the pooled cohort equations in NHANES, 86.6% of adults (78.1% of men and 95.2% of women) aged 40 to 50 years had a risk lower than 5%. This analysis considered all adults, including those with ASCVD, diabetes, and other risk equivalents (4) . Of greater importance, these studies did not examine the risk distribution of different subgroups based on individual risk factors, such as smoking and hypertension; this is relevant because one might argue that if 4% of the population between the ages of 30 and 39 years had a risk greater than 10%, repeated screening of this age group would be reasonable. Our study reveals that the overwhelming majority of those at high risk are smokers and, to a lesser degree, nonsmokers with hypertension.
Our study has several strengths. We examined the prevalence of increased cardiovascular risk in a nationally representative sample of healthy young adults. By choosing risk factors that are readily available (age, sex, smoking status, and hypertension) we could easily identify groups of patients for screening. In our sample, approximately one third of tests among men and two thirds among women younger than 50 years could be avoided with minimal effect. At the same time, our study emphasizes the importance of smoking as a risk factor in younger patients. Almost all smokers had at least a 5.5% chance of elevated risk, regardless of age or sex. This finding mirrors a recent observation that among patients younger than 50 years, smoking was associated with a risk for myocardial infarction 8 times greater than that of nonsmokers (30) .
Our study also has several limitations intrinsic to the NHANES study design. Risk factors and family history were self-reported by participants. Low-density lipoprotein cholesterol values were present only in the morning examination subsample. We also excluded patients who were receiving a statin or other lipidlowering drug at their initial visit. Sensitivity analyses including those participants produced similar results. We measured predicted risk, not actual cardiovascular outcomes. However, because treatment under the ACC/AHA guidelines, as well as the USPSTF guidelines, is based on predicted risk, our analysis reveals the likelihood that screened patients would be eligible for treatment, which is strongly associated with reduced events (31) . Finally, we used a conservative risk cutoff of 5% to identify a population that might benefit from therapy directed toward lowering cholesterol levels. Some have argued that the pooled cohort equations overestimate ASCVD risk (10, 11) . Using a different calculator or a higher cutoff would make screening the low-prevalence population even less attractive.
In a nationally representative adult population, the prevalence of elevated cardiovascular risk in the absence of smoking or hypertension is low in men younger than 40 years and women younger than 50 years. One-time screening of the entire population might be useful in identifying persons with very high LDL-C levels, suggesting possible genetic hyperlipidemias. Targeted screening of young adults with a family history of premature heart disease is not more likely to identify those with very high LDL-C levels.
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